Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.

about

Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.

Item

http://www.wikidata.org/entity/Q35969785

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.

@ast

Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.

@en

type

Item

label

Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.

@ast

Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.

@en

prefLabel

Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.

@ast

Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.

@en

P1476

Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.

@en

P2093

Byung Gyu Kim

http://www.w3.org/2001/XMLSchema#string

Chang-Ki Min

http://www.w3.org/2001/XMLSchema#string

Cheol-Kyu Jung

http://www.w3.org/2001/XMLSchema#string

Eok Park

http://www.w3.org/2001/XMLSchema#string

Ji-Young Lim

http://www.w3.org/2001/XMLSchema#string

Jonghoon Park

http://www.w3.org/2001/XMLSchema#string

Kwang-Ai Won

http://www.w3.org/2001/XMLSchema#string

Seung-Wan Kang

http://www.w3.org/2001/XMLSchema#string

Sung-Eun Lee

http://www.w3.org/2001/XMLSchema#string

Tae Hun Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Targeted treatments for multiple myeloma: specific role of carfilzomib

ER stress-induced cell death mechanisms

Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation.

The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing.

Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation

The ubiquitin-proteasome pathway: on protein death and cell life

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.

United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.

P2888

s12885-016-2285-2

P304

247

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12885-016-2285-2

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

299420436

http://www.w3.org/2001/XMLSchema#string

P6179

1023442080

http://www.w3.org/2001/XMLSchema#string

P698

27012957

http://www.w3.org/2001/XMLSchema#string

P932

4806471

http://www.w3.org/2001/XMLSchema#string